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1. APOBEC3 (A3) enzymes deaminate single-stranded DNA, mutating viral 
genomes 
 
2. Tumors harbor mutations likely due to off-target A3 deamination of 
chromosomal DNA 
 
3. A common APOBEC3 deletion polymorphism increases breast cancer risk 
 
4. A growing body of evidence points to a driver role for APOBEC3s in 
tumorigenesis 
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Abstract 
The APOBEC3 cytosine deaminases play key roles in innate immunity through their 
ability to mutagenize viral DNA and restrict viral replication. Now recent advances in 
cancer genomics, together with biochemical characterization of the APOBEC3 
enzymes, have implicated at least two family members in somatic mutagenesis 
during tumor development. Here we review the evidence linking these enzymes to 
carcinogenesis and highlight key questions, including the potential mechanisms that 
misdirect APOBEC3 activity to the host genome, the links to viral infection, and the 
association between a common APOBEC3 polymorphism and cancer risk. 
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Deoxycytidine deamination in innate immunity and somatic mutagenesis 
The human apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 
(APOBEC) gene family comprises 11 genes: the Activation-Induced Cytidine 
Deaminase (AICDA), APOBEC1 (A1) and seven A3s encode (deoxy)cytidine 
deaminases capable of targeting RNA and/or DNA; A2 does not appear to posses 
catalytic activity and A4 remains uncharacterized [1]. The founding member, A1 was 
cloned over 20 years ago and shown to be responsible for the deamination (see 
Glossary) of cytidine 6666 in the ApoB mRNA, converting it to uridine and generating 
a stop codon that creates a shorter ApoB48 protein [2, 3]. AICDA encodes Activation-
induced Deaminase (AID) which deaminates deoxycytidine (dC) in single stranded 
(ss) DNA, generating deoxyuridine (dU), an activity that underlies somatic 
hypermutation (SHM) and class switch recombination (CSR) to drive antibody 
diversification in B-lymphocytes (reviewed in [4, 5]). The discovery that A1 and 
several A3s are also able to deaminate dC (in some cases with greater potency than 
AID) in ssDNA [6] led rapidly to an understanding that this DNA editing activity forms 
a key part of the innate immune response to viral infection, the best-characterized 
example of which is the human immunodeficiency virus (HIV) restriction factor A3G 
[7, 8]. Like all the A3 enzymes, A3G can only target ssDNA, in this case the nascent 
proviral HIV cDNA during reverse transcription [8]. The direct deamination action is 
dC>dU in the minus strand reverse transcript, particularly at CC dinucleotides. 
However, the edited mutations are subsequent G>A transitions in the coding 
positive strand, inactivating the provirus [7, 9]. The HIV protein Vif (viral infectivity 
factor) allows the virus to overcome this response by hijacking a cellular E3 ubiquitin 
ligase (CUL5) to mark A3G for proteasomal degradation [10, 11].  
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While A3G resides in the cytoplasm, where it becomes incorporated into retroviral 
virions, A3 enzymes such as A3A, A3B and A3C enter the nucleus, where they are 
able to target other pathogens including human papillomaviruses (HPV) and also 
retrotransposons; mobile elements within the genome which appear to be targeted 
by multiple APOBEC enzymes via a variety of mechanisms [12-19]. With nuclear 
localization however, comes the risk of off-target activity against host genomic DNA 
and the potential for mutagenesis. Normally, genomic dU resulting either from dC 
deamination or mis-incorporation of deoxyuridine monophosphate (dUMP) during 
replication is efficiently removed by Uracil-DNA Glycosylase (UNG) and lesions are 
resolved by the Base Excision Repair (BER) pathway. Failure to replace dU with dC 
before the next round of replication leads to mutations, the precise nature of which 
depend upon the point at which replication interrupts repair and also on the 
polymerases involved.  
 
The mechanistic details of these events following deamination by A3s remain 
uncharacterized, but working models have been proposed based upon what is 
known about AID-dependent SHM [5, 20-22]. As summarized in Figure 1, replication 
prior to removal of dU can result in C>T transitions due to incorporation of dA into 
the daughter strand through Watson-Crick base pairing. Alternatively, following 
removal of dU by UNG, translesion synthesis (TLS) polymerases can replicate over 
the resulting abasic site, most commonly inserting dA in the daughter strand (the ‘A-
rule’), again resulting in C>T transitions. Other TLS polymerases insert different 
deoxynucleotides opposite abasic sites; Rev1 for instance, uses dC, resulting in C>G 
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transversions at deaminated sites in yeast [23, 24]. If deamination were to occur in 
close proximity on both strands, double strand breaks (DSBs) could result, with the 
overhangs either chewed back by exonuclease, or filled in by polymerase (Fig 1). 
Here we discuss recent evidence linking off-target activity of A3s to somatic 
mutagenesis during tumor development. We highlight important questions 
regarding how and why A3s turn against chromosomal DNA, and how a 
polymorphism affecting A3A and A3B has come to vary so widely across the human 
diaspora. 
 
APOBECs as mutators of genomic DNA: the cancer connection 
Early evidence for a link between APOBECs and cancer came from transgenic 
animals, with overexpression of APOBEC1 (A1) in mice giving rise to hepatocellular 
carcinomas [25]. The finding that AID and A1 could cause mutations in DNA when 
expressed in E. coli provided not only a clue to how AID drives antibody 
diversification but also a mechanism by which APOBECs might promote tumor 
formation [6, 26]. Soon afterwards, AID was shown to cause lymphomas with 
mutations in c-MYC in transgenic mice and also to mediate the IgH-MYC 
translocations seen in Burkitt’s lymphomas [27, 28]. In another key study, Beale and 
colleagues examined the substrate specificity of AID, A3G and A1, and noticed an 
enrichment for C>T mutations within TP53 and APC; tumor suppressor genes that 
had been heavily sequenced in cancer samples, even at that time [29]. Later, it was 
shown that infection of gastric epithelial cells with Helicobacter pylori induces AID 
expression, leading to TP53 mutations; one mechanism by which H. pylori infection 
may cause gastric cancer [30].  
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The recent application of next generation sequencing to model systems and cancer 
samples has provided support for A3 involvement in somatic mutagenesis, and has 
also begun to shed light upon the mechanisms by which this process occurs. Initially 
working in yeast, Roberts and colleagues demonstrated that chronic exposure to the 
DNA alkylating agent, methyl methanesulfonate (MMS) resulted in clustered 
mutations; primarily point mutations at C:G base pairs [31]. Importantly, these 
mutations were strand-coordinated (i.e. ‘long series of either mutated cytosines or 
mutated guanines in the sequenced strand’), indicating that: (i) that they had arisen 
from a specific lesion affecting multiple cytosines or guanines in a long stretch of 
ssDNA (based on the mechanism of action of MMS, they postulated this to be N3-
methyl cytosine; a ssDNA-specific lesion); and (ii) that they had occurred 
simultaneously (chronocoordinate), or at least within one cell cycle. Also apparent 
was strand switching, in which runs of mutated cytosines were followed by runs of 
mutated guanines, or vice versa. This suggested that the mutations could be 
occurring in stretches of ssDNA that became exposed during bidirectional 5’ to 3’ 
resection either side of DSBs. The use of mutants with replication fork dysfunction 
suggested that in addition to DSBs, stalled replication forks were also sources of 
ssDNA that gave rise to strand coordinated clusters. Next they looked at sequence 
data from three cancer types (head and neck (HNSC), prostate and multiple 
myeloma) and observed similar clusters of C- or G-coordinated clusters, often 
occurring close to chromosomal rearrangement breakpoints [31].  
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At the same time, Nik-Zainal and colleagues were extracting mutational signatures 
(Box 2) from breast cancer sequence data, and also noticed evidence of mutation 
clusters [32]. These clusters were also characterized by strand-coordinated 
mutations at C:G base pairs. Noting the similarity of these clusters to the multi-
kilobase chronocoordinate mutation showers previously described in transgenic 
mice expressing a lacl reporter gene (and predicted to occur in cancer) [33], they 
termed them kataegis (after the Greek kataegisa meaning thunder shower, or 
tempest) [32]. Both studies [31, 32] noticed that the predominant mutations 
occurring in these clusters were C>T or C>G substitutions within the optimal 
substrate motif (TpCpW, where W = A or T) for a subset of ‘TC-specific’ A3s including 
A3A, A3B, A3C, A3F and A3H. Since A3s are known to be specific for ssDNA and to act 
processively along stretches of ssDNA [34], they were proposed in both papers as 
candidates for producing mutation showers in tumors [31, 32].  
 
Independently, building upon their earlier demonstration that A3B expression is 
often dramatically elevated in cancer compared to normal tissues [6], Harris and 
colleagues found that A3B expression is correlated with the extent of cytosine 
mutations in breast tumors, and that deoxycytidine deaminase activity in nuclear 
extracts from breast cancer cell lines is abolished by A3B knockdown [35]. In the 
same study, A3B knockdown also reduced genomic uracil loads and mutagenesis of a 
thymidine kinase reporter gene. A role for A3B in generating kataegis in tumors is 
also supported by studies showing that it can induce similar mutation showers when 
overexpressed in yeast, as can A3A [24]. Subsequent pan-cancer screens by all three 
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groups suggest a mutagenic role for one or more of the TC-specific A3s in numerous 
tumor types [36-38].  
 
Mechanisms of A3 deregulation 
A3-mediated mutations, whilst reminiscent of AID-dependent SHM, are clearly an 
off-target activity occurring in some, but not all, cancers. We know little as yet 
regarding how and why A3s become deregulated in tumors, but we discuss some of 
the possible factors leading to changes in A3 expression or activity, availability of 
ssDNA substrate and mutagenesis rather than repair of deaminated dC. 
 
A3 expression and stimulation 
Although there is a bias in publicly available datasets, it does appear that A3 
mutagenesis is particularly prevalent in carcinomas [36-38]. This may be because 
epithelia are a front-line barrier to viruses, and hence the innate immune response, 
including A3 viral restriction, is more primed or active in these cells. A3B is highly 
expressed in tumor types with enrichment of A3 mutation signatures [37, 38], and its 
expression correlates with prevalence of A3 signatures in breast and ovarian cancers 
[22, 35]. Much attention therefore, has focused on A3B as an agent for genomic 
mutations. 
 
At first glance though, this is difficult to reconcile with genetic evidence that the 
A3A_B deletion polymorphism, where the entire A3B protein coding sequence is 
missing, carries an increased risk of breast cancer [39, 40]. Furthermore, a recent 
reanalysis of public breast cancer mutation data reported higher levels of A3 
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mutation signatures in patients harboring a copy of A3A_B, and more still in 
homozygotes (albeit there were very few of the latter), consistent with the A3A_B 
form (essentially A3A fused to the A3B 3’ untranslated region (UTR)) being more 
mutagenic [41]. 
 
A possible resolution of this quandary comes from Wain-Hobson and colleagues who 
transfected an artificial A3A_B construct into human cells. The resulting protein 
product was expressed at 20-fold higher levels than an A3A construct, and showed a 
potent hyperediting activity on nuclear DNA [42]. A possible (but as yet unexplored 
inference) is that the A3A 3’UTR is normally targeted by one or more micro-RNAs 
that repress A3A expression, and that this repression is relieved in the A3A_B allele, 
in which A3A is instead fused to the A3B 3’UTR (Box 1). Regardless of the 
mechanistic details, it suggests that although A3B is expressed at much higher levels 
in some tumors (e.g. breast), in some circumstances A3A can be the more potent 
mutagenic enzyme. Teasing apart exactly which A3 is responsible for A3 signatures in 
tumors is hampered by the close similarity of the proteins. Localization of A3A and 
A3B expression by immunohistochemistry for example, has thus far been impossible 
due to a lack of suitable antibodies.  
 
In addition to differential baseline expression of A3 enzymes, another intriguing 
possibility is that stimulation following viral infection could increase off-target A3 
genomic mutations. The preponderance of A3 mutations in HPV driven cervical 
cancer, together with the observation that A3 mutations are enriched in the HPV-
associated subset of head and neck squamous cell carcinoma (HNSC), suggest a 
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possible off-target response to the virus [37, 38, 43, 44]. Consistent with this, HPV16 
infection has recently been shown to upregulate A3A and A3B mRNA expression in a 
keratinocyte cell line, and both are upregulated in pre-invasive cervical lesions [19, 
45]. However, within cervical cancer and HNSC the enrichment of A3 signature 
mutations is not related to the expression of A3 genes, at least as seen in the tumor 
biopsy [43, 44]. Of course, it could be that when the mutations are occurring during 
development of these tumors, they are correlated with the expression of the A3 
responsible, but that this relationship is lost following subsequent downregulation; a 
possibility alluded to by Roberts and Gordenin in their discussion of A3s as transient 
hypermutators [46]. Further, in hepatocytes expression of several A3s increases 
following hepatitis B virus (HBV) infection [47]. However there is no sign of off-target 
A3 mutations following this response, nor are they evident in HBV-associated 
hepatocellular carcinomas [43, 48]. 
 
Existing expression of A3 enzymes, or increased expression due to viral stimulation, 
may be important, but is unlikely sufficient to cause A3 deregulation. As yet there is 
little direct evidence of what else needs to go wrong, but perhaps an intriguing hint 
comes from a small study of chronic lymphocytic leukemias (CLL). CLL arise from B 
cells, and an A3-like kataegis signature was reported within CLL samples that had 
undergone SHM (IgV-Mut), but not in samples that had not (IgV-UM), whilst the 
expression of A3A and A3B proteins was unchanged [49, 50]. Although it remains 
necessary to establish whether this holds true in a larger sample set, it does suggest 
a common mechanism may have caused permissiveness both for AID-driven SHM 
and A3-mediated kataegis. Highly related nuclear localization sequences (NLS) have 
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been described in AID and A3B [51], raising the possibility that a common signal 
could stimulate the nuclear translocation of both, explaining the co-occurrence of 
the AID and A3 mutational signatures. Another possibility is switching to a specific 
error-prone pathway that processes genomic uracil in B cells undergoing SHM [52]. 
The finding that IgV-UM CLL express more AID than IgV-Mut CLL [53] also argues that 
a switch is necessary before AID becomes mutagenic, even in tumor cells. The same 
is possibly true of A3s. 
 
Whilst the best-characterized activity of A3G against exogenous retroviruses 
requires cytoplasmic localization, all seven A3 genes have the ability to inhibit 
nuclear retrotransposon activity, albeit with differing potencies [12, 14, 15]. The 
single domain A3s (A3A, C and H), at around 23kDa are able to enter the nucleus via 
passive diffusion, whereas the larger A3B, D, F and G require an active import 
mechanism [14]. A3B contains a NLS and localizes to the nuclei of transfected cells, 
while A3D, F and G are cytoplasmic and do not appear to come into contact with 
DNA, even following breakdown of the nuclear envelope during mitosis [13, 14, 54]. 
It is possible that these cytoplasmic A3s inhibit retroelements in an indirect manner 
distinct from the deamination-based inhibition by A3A [16, 17]. Again, the close 
similarity between the A3s is an obstacle to study of their subcellular localization. 
The current picture comes largely from studies on overexpression of epitope-tagged 
proteins, which may behave differently from endogenous A3s. This issue has been 
addressed recently in the study of endogenous A3A localization in monocytes; a cell 
type with high endogenous A3A expression. In monocytes it appears there is a 
mechanism absent from other cell types that keeps A3A in the cytoplasm and 
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prevents it from damaging the genome [55].  Different polymorphisms in A3H have 
been shown to alter its subcellular localization, which suggests the affected amino 
acids play a role in blocking the passive diffusion of this enzyme between cytoplasm 
and nucleus [56]. 
 
Finally, in a cohort of 115 cervical cancers, missense mutations in A3 family genes 
(A3B, A3F and A3G) were found in four samples [44]. In each of these samples TpC 
mutations accounted for at least 70% of the total mutational load, and two had the 
highest nonsilent mutation rate amongst the cohort. Indeed, the two most heavily 
mutated samples harbored phenylalanine substitutions at a conserved serine in both 
A3B and A3F. Although functional analysis of the mutants was not presented, this 
observation suggests that occasionally gain of function mutations in A3s may play a 
driver role in cancer development. Irrespective of the mechanism, it seems likely 
that the evolutionary differentiation of A3 enzymes in humans, which are under 
selective pressure, has arisen to target specific viral insults in specific cells whilst 
carefully regulating their potential for self-harm.  
 
Availability of ssDNA substrate 
As A3s are only able to target ssDNA, the availability of this substrate is likely often a 
limiting factor for A3-mediated mutagenesis in tumor cells. ssDNA exposed during 
the resection stage of DSB repair is vulnerable to mutations, and kataegis is often 
associated with rearrangement breakpoints in human tumors [31, 32]. In addition to 
rearrangements, segmental amplifications or deletions (CNVs) also involve DSBs. 
Among breast cancers, the HER2-amplified subset displays the greatest enrichment 
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for A3 signature mutations [38] and also displays elevated markers of genomic 
instability, harboring twice the number of CNVs seen in other breast tumors [57, 58]. 
Breaks associated with CNVs may be an important source of ssDNA substrate in 
tumors such as these, although they are not correlated with A3 signature 
enrichment across multiple tumor types, at least as measured using exome 
sequencing data [38]. In yeast models A3-induced kataegis was potentiated by, and 
occurred close to, targeted DSBs introduced using a restriction endonuclease [24]. In 
the absence of endonuclease-induced DSBs, mutation showers induced by 
heterologous expression of cytosine deaminases are dependent upon UNG, which is 
required for the creation of DSBs following removal of uracil from opposing strands 
(as occurs during AID-induced class-switch recombination; Figure 1), [24, 59]. A3-
mediated kataegis may therefore be either self-seeding or associated with DSBs 
arising via other mechanisms. Since they are associated with chromothripsis, both 
spatially and temporally (at least in breast cancer) [32, 60], this raises the question of 
whether kataegis is triggered by chromothripsis, or possibly vice-versa? 
 
Another source of kataegis could be stretches of ssDNA exposed at stalled or 
collapsed replication forks. Yeast mutants with increased fork stalling display 
increased mutation showers upon MMS exposure [31] and fork stalling is a common 
feature of transformed cells; a consequence of replication stress caused by 
unregulated S-phase entry [61]. Further work in yeast has revealed that break-
induced replication (BIR), a highly conserved mechanism for the repair of DSBs 
occurring at collapsed replication forks or eroded telomeres produces long stretches 
of ssDNA, resulting in kataegis-like mutation clusters [62]. The authors suggest that 
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BIR arising from defects in replication, rather than strand resection during the repair 
of DSBs, could account for the longer stretches of strand-coordinated editing seen in 
some kataegis events. Replication stress and A3-induced mutagenesis have recently 
been linked to loss of a chromosomal fragile site gene, FHIT [63].  FHIT is frequently 
lost very early in tumor development, causing replication stress due to 
deoxythymidine triphoshate (dTTP) depletion [64]. When genomic sequences from 
lung adenocarcinomas were stratified by A3B and FHIT expression, those with high 
A3B and FHIT loss showed significantly higher A3 signature mutation loads than high 
A3B expressers with normal FHIT levels, thus the mutagenic potential of A3B may be 
unleashed in the absence of FHIT [63].   
 
In addition to BIR, mismatch repair (MMR) has also been implicated in A3-mediated 
mutagenesis. When Furano and colleagues introduced episomes with specific 
mismatches into human cell lines they observed that while the mismatches were 
repaired, the flanking sequences frequently incurred TpC mutations characteristic of 
A3 activity [52]. Knockdown experiments showed that these A3-like mutations were 
dependent upon A3 expression and BER and MMR proteins. They proposed a model 
in which A3 mutations occur when the BER pathway is “hijacked” by a non-canonical 
MMR mechanism: the same pathway deployed during AID-dependent 
immunoglobulin SHM [52]. Indeed, the activation of such a pathway might explain 
the co-existence of AID- and A3-dependent mutation clusters in CLL [50]. 
 
Another possible exposure of ssDNA to A3s is in the transcription bubble. 
Transcription bubbles, structures in which ssDNA is exposed due to helicase activity 
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of the RNA polymerase complex, are known targets of AID [65-68] and represent a 
likely source of mutations in coding regions if replication occurs before repair of dU. 
In bladder cancer, A3 mutations are enriched in highly transcribed genes, particularly 
on the sense strand [69], suggesting that A3s also act on ssDNA during transcription. 
It is possible that a transcription-coupled repair pathway may suppress mutagenesis 
on the coding strand, although the evidence linking repair of deaminated dC to 
transcription remains controversial [70]. Alternatively, this strand bias is reminiscent 
of transcription-coupled AID mutagenesis, which acts upon structures called R-loops, 
in which the non-coding strand is selectively looped out and deaminated while the 
coding strand is hybridized to the primary transcript and thus protected [71].  
Several mechanisms that have been posited to expose stretches of ssDNA to A3 
activity are depicted in Figure 2.  
 
Failure of DNA repair pathways 
In HNSC and breast cancers a linear relationship between A3 signature mutations 
and other point mutations across cancers with widely varying mutational loads is 
observed [35, 43], consistent with a model in which various mutagenic processes are 
kept in check by DNA repair mechanisms and only manifest when these pathways 
fail. In B cells, for instance, the mutagenic activity of AID is restricted outside of SHM 
by a combination of BER and MMR [72]. Since mutagenesis at dU likely occurs when 
BER is interrupted by TLS (Figure 1), it is possible the unregulated progression 
through S-phase that occurs following loss of cell cycle checkpoint control during 
transformation acts to increase the mutagenic effect of A3 activity. Specific defects 
in DNA repair pathways have not been linked to the appearance of the A3 signature 
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in tumors however, and it may be the case that the repair pathways remain 
functional but unable to cope with increased rate of mutation following A3B 
upregulation [35], aberrant A3 localization or increased exposure of ssDNA. 
 
In summary, many mechanisms may expose DNA to A3 deamination and a number 
of in vitro models have replicated kataegis-like phenomena. However even within 
and between different breast cancer samples a mixed presentation of A3-like 
mutations within large rearrangement-associated kataegis macroclusters, or 
sporadically throughout the genome, or with varying proportions of transition or 
transversion can be observed [32]. Indeed, a recent analysis of ovarian cancer has 
linked C>A transversions to A3B activity, with the implication that a different TLS 
polymerase may act on abasic sites caused by cytosine deamination in these tumors 
[22] (Figure 1). This suggests that many of the proposed models of A3-mediated 
mutagenesis maybe valid, and that together with increased A3A or A3B expression 
(as occurs during HPV infection, for example) there are multiple points of failure in 
DSB repair, replication or transcription that might potentiate A3 off-target activity, 
even within cancers arising in the same tissue. 
 
A3 mutations: passengers or drivers? 
An important question arising from the finding of widespread A3 mutations in many 
tumor types is whether this is a bystander phenomenon occurring as a result of a 
chaotic tumor genome, or whether the A3 mutational process contributes to tumor 
development. Transgenic expression of AID and A1 are tumorigenic in mice, and C>T 
mutations suggestive of AID/APOBEC involvement were previously noted in TP53, 
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MYC and APC [25, 27, 29, 30]. In exome data, enrichment of A3 mutations amongst 
putative cancer driver genes as defined by either the catalogue of somatic mutations 
in cancer (COSMIC) database [73] and/or the MutSig collection [74] of recurrently 
mutated genes  [38, 43] have been observed. Upon inspection of the genes most 
frequently A3-mutated in HPV-associated cancers, the PIK3CA proto-oncogene is 
almost exclusively mutated at two helical domain hotpots (E542K and E545K) [43]. 
These are always G>A substitutions within the ApGpT context, thus the result of 
TpCpA transitions on the noncoding strand.  Indeed, PIK3CA helical domain 
mutations are strongly correlated with A3 mutation enrichment across multiple 
tumor types, while an equally oncogenic and prevalent hotspot mutation (H1047R), 
which is not caused by an A3 signature mutation is largely confined to tumor types 
with reduced enrichment for this signature across the exome [43]. These 
observations, together with the finding that PIK3CA helical domain mutation 
coincides with appearance of the A3 signature in lung cancer subclones [75] strongly 
implicate A3 activity in generating these driver mutations. 
 
Accumulating evidence suggests that the stage of tumor development at which the 
A3 signature appears varies considerably between tumor types. Analysis of 
metachronous paired samples representing early superficial noninvasive (Ta) and 
subsequent invasive (T1/T2) bladder tumors both displayed the A3 signature equally 
[69]. In breast cancers, A3 mutations begin to accumulate early but make a greater 
contribution to the mutational load (particularly C>G transversions) of later 
subclones, suggesting an increasing fraction of A3 mutagenesis as the tumors evolve 
[60]. The same study revealed evidence of distinct kataegis events occurring at 
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separate points during the development of a given tumor. Similarly, in non-small cell 
lung adenocarcinomas a recent evolutionary analysis of dissected subclones showed 
the A3 signature is weaker early in the evolution of disease (when tobacco-
associated mutations predominate) but appears strongly in subclones [75]. This 
pattern was also apparent in lung adenocarcinomas but not in lung squamous 
carcinomas. In summary, there is no simple pan-cancer story of A3 mutagenesis. 
There is variation even between different histological subtypes arising in a common 
tissue, however it appears that A3 mutagenesis contributes to the early 
development of certain tumors, and can still fuel metastasis and/or drug-resistance 
at advanced stages by driving the evolution of tumor subclones. 
 
Concluding remarks and future perspectives 
The discovery of A3 signature mutations, and more broadly the dissection of 
recurring mutational signatures across cancers, has been a highlight of the effort to 
collect and “data-mine” the tumor databases. Based upon the current literature, we 
can speculate on the causes and consequences of A3-mediated mutagenesis in 
tumor development (Figure 3), but it is essential that these observational studies are 
followed by further experimentation before we can confidently link these signature 
mutations to A3 activity. To date, of the 11 APOBEC genes in humans only A1 and 
AID have been shown to cause tumors when overexpressed in mice [25, 27]. 
Conversely, A3 loss-of-function experiments in models of tumor development are 
also currently lacking, as are studies testing the models of A3-mediated mutagenesis 
that have been proposed based upon AID function in lymphocytes. Indeed, whilst a 
diversity of A3 signatures in tumors is observed (from none to many, from sporadic 
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to clustered kataegis, and from early beginning to late developing), specific patterns 
in specific tumors in vivo have not been associated with the putative mechanisms 
discovered in vitro. This would be an important step forward, as the mutational 
signature of a particular tumor could serve as a genomic readout of the underlying 
physiological problems occurring in DNA repair pathways of that tumor. This could 
open up new avenues of data-mining in the tumor databases as we might relate 
types of A3 signature (rather than just their quantity) to different polymorphisms, to 
expression signatures, or mutations of specific genes and pathways. DNA repair 
pathways have become drug targets either to prevent therapeutic resistance or kill 
cancer cells dependent upon particular pathways [76]. A genomic readout indicating 
which DNA repair pathways are dysregulated would provide useful guidance for this 
work. 
  
Further observational work on A3 mutational signatures is likely to follow the 
general trend of cancer genomics, which is to recognize cancer as an evolving clonal 
disease. Early indications are that A3 signatures arise early in some tumors whilst in 
others they appear more strongly in later subclones. These analyses will continue as 
we seek to understand whether A3 signatures may point to preventive therapies or 
possibly could be biomarkers of early disease. 
  
Finally, the association between A3 polymorphisms, mutagenic potential and cancer 
risk is particularly intriguing. The dramatic effect that underlying genetics and/or 
environmental factors can have on mutational signatures was recently highlighted by 
a global analysis of hepatocellular carcinoma (HCC), in which cancers of Japanese, 
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European and US-Asian patients were characterized by different mutational 
signatures [77]. Given the association of the A3 chimeric polymorphism with breast 
cancer, one is left wondering why it has increasingly gained prevalence outside of 
African populations. Cancer genome studies from more diverse populations may 
help us untangle the competing selective pressures behind the evolution of the A3 
family.  
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Box 1: Evolution and population variation within the A3 gene family 
The A3 genes have evolved and diversified extensively throughout mammalian 
evolution, and still show signs of ongoing selective pressure in humans. The ancestral 
A3 enzyme evolved from the ancestral AID cytidine deaminase that is widespread 
throughout vertebrates. The mouse genome has a single A3 gene, the dog has two, 
but there are four in cats, six in horses and seven in primates, with the human A3 
family all residing within a single 100 kb region on chr22 (A3A, A3B, A3C, A3D, A3F, 
A3G, A3H). This complexity has arisen from a series of duplications and fusions 
amongst three ancient clades of A3 genes (A3Z1-A3Z3) established subsequent to 
the evolution of placental mammals some 100 million years ago (A3 homologs are 
not found in monotremes or marsupials) [78-80]. For instance, the human A3A gene 
arose from A3Z1, and the human A3B gene arose from fusion of A3Z1 and A3Z2 
genes (Figure I). The close relatedness of A3 genes presents a challenge to 
researchers studying the expression and functions of the different family members. 
 
Adding further diversity, a common deletion polymorphism between A3A exon 5 and 
A3B exon 8 produces an A3A_B fusion transcript, completely removing the A3A 
3’UTR and A3B CDS. This allele, in which the A3A CDS is linked to the A3B 3’UTR 
displays a remarkable geographical gradient across the human population; rare in 
Africans (~1%), but found in 6% of Europeans, 37% in East Asians, 58% in 
Amerindians, and 93% of Oceanians [81]. This suggests that A3B may be under 
competing selective pressures, speculatively with the full A3B protective against a 
particular African pathogen but progressively lost as humans migrated further out of 
Africa. Other A3 genes also display a variety of haplotypes, including A3H, in which 
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SNPs common in the African population confer increased stability, altered 
subcellular localization and enhanced anti-retroviral function to the resulting 
proteins [56, 82-84]. 
 
 
Box 2: Extracting mutation signatures 
The “mutational portraits” of different cancers are composed from differing 
quotients of many distinct mutational processes, and the snapshot at the point a 
tumor sample is sequenced is an accumulation of the history of these processes and 
a combination across the heterogeneity of the tumor sample [85]. Extensive 
sequencing across many samples is required so that recurrent and overlapping 
mutational processes can be teased apart into their constituent signatures. Recently 
a breakthrough in the study of point mutation processes in cancer came with the 
analysis of a large collection of many thousands of tumor samples using the Non-
Negative Matrix Factorization (NMF) algorithm [36]. For the cancer genome study it 
was used to separate up to 20 distinct mutational signatures from the noisy 
overlapping collection of signatures, including two signatures dominated by C>T and 
C>G mutations at TpC sites, indicative of A3 activity. Exogenous damage processes 
underlie other signatures, including UV radiation on dipyrimidines (CC>TT) strongly 
apparent in melanoma, whilst (G>T) transversions associated with smoking 
proliferate in lung cancers, and spontaneous deamination at methyl-CpG sites 
leading to transitions (C>T) are a common age-associated phenomenon throughout 
many types of cancer [36]. The separation of these mutational signals can give 
insight into the driving forces behind tumorigenesis. For instance, a study of 
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esophageal cancers has revealed a quite unique signature of (AA>AC) transversions 
making up to 29% of all substitutions in this tumor [86]. It is likely that this reveals a 
particular mutagenic effect associated with gastroesophageal reflux, raising 
possibilities for esophageal cancer prevention or surveillance. When one is 
interested in the extent to which a specific mutational signature might be enriched 
in a particular tumor or subset of tumors, methods such as NMF can be 
complemented by calculating the observed frequency at which the signature 
mutations occur in an exome or genome versus that expected by chance, allowing 
statistical comparison between individual samples. This approach has been used to 
identify enrichment for A3 signature mutations in HER2-amplified breast cancer and 
HPV-associated HNSC, for instance [38, 43, 87]. In addition to the signatures arising 
from external DNA damaging processes, endogenous error in the replication or 
repair process may introduce errors independently, or if defective, fail to properly 
repair the normal physiological range of DNA damage properly. How these repair 
and replication processes fail in different cancers may also modulate the mutation 
signature, and is a fertile new field in mutation research [88].  
 
Box 3: Outstanding questions 
1. How does the A3 innate immune system become deregulated in cancer? Is it 
an excess of DNA damage creating substrate, or failure of the downstream 
correction pathways? Is increased A3B expression sufficient? Does loss of a 
regulatory switch misdirect A3 activity to the genome? 
2. Is A3B uniquely harmful but protective against an African pathogen, hence its 
retention there and loss elsewhere? Why is it harmful?  
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3. The A3A_B polymorphism predisposes to breast cancer but does it affect risk 
of developing other cancers, in particular those such as bladder and HPV-
related cancers, in which A3s appear to play a prominent role in 
tumorigenesis? 
4. Which A3 is primarily responsible for somatic mutagenesis during cancer 
development and does the A3 family member involved vary from one cancer 
to another? 
5. Could viral infections, even those subsequently cleared, cause potentially 
cancer-initiating mutations in our DNA by triggering an A3 response? 
6. Does A3 activity contribute significant numbers of DSBs in cancer cells? Could 
A3s be responsible for a portion of the insertion/deletions, rearrangements 
and even chromothripsis observed in certain tumors?  
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Glossary 
Base excision repair (BER): The major pathway by which deaminated cytosine is 
repaired, involving removal of the damaged base by a 
DNA glycosylase (UNG) to create an apyrimidinic (AP) 
site, nicking of the phosphodiester backbone on the 
affected strand by an AP endonuclease (e.g. APE1) and 
then replacement of the cytosine and ligation to 
complete repair. Problems occur when this process is 
interrupted by replication via the action of TLS 
polymerases. 
Chromothripsis: From the Greek meaning chromosome shattering, in 
which many rearrangements are observed in a 
chromosome region suggesting fragmentation 
followed by error-prone DSB repair. 
Break-Induced replication:  A specialized variant of replication that is used for the 
repair of single-ended DSBs such as those occurring at 
collapsed replication forks and eroded telomeres. BIR 
creates very long stretches of ssDNA, presumably a 
prerequisite for A3-mediated kataegis and is highly 
conserved throughout eukaryotes although so far, 
evidence linking it to kataegis is restricted to yeast 
models. 
Deamination: Here refers to the removal of an NH2 group from a base 
in RNA or DNA (commonly cytdidine/deoxycytidine, in 
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which case the product is uridine/deoxyuridine 
respectively). 
Exome: Refers to the coding portion of the genome. This 
comprises only around 1% of the genome and is thus 
cheaper to sequence and the data generated are more 
straightforward to analyze. 
Human papillomaviruses (HPV):  Small double stranded DNA viruses with a 
tropism for either mucosal or cutaneous epithelia. 
High-risk mucosal variants (e.g. HPV16) cause almost 
all cervical cancers and a subset of head and neck 
squamous carcinomas. 
Hypermutator: The term used to describe certain cancer samples that 
are statistical outliers, displaying many more mutations 
than other tumors of a similar type. In hypermutated 
breast cancers, many of these mutations are of the A3 
type and these are the samples in which kataegis 
events are commonly seen. 
Mismatch repair (MMR): A mode of post-replication repair in which the parental 
strand is used as a template from which to recognize 
and repair mismatches in the daughter strand that 
have occurred during replication. 
Replication fork: The structure formed by the replication complex, at 
which point helicases have separated the two DNA 
strands to allow replication.  
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Retrotransposons: Retrotransposons are mobile elements (essentially 
endogenous retroviruses) that make up around 40% of 
human genomic DNA. They proliferate via transcription 
to RNA, followed by reverse transcription and re-
integration. They are divided into two broad groups:  
the viral long terminal repeat (LTR) transposons, and 
the long (LINE-1/L1) and short (SINE) interspersed 
elements. Retrotransposons cause inherited disorders 
and cancer through insertional mutagenesis. 
Transition mutation: A mutation in which one purine is replaced by another, 
and hence one pyrimidine is replaced by another on 
the complementary strand (and vice-versa). 
Translesion synthesis (TLS): The mode of replication in which specialized DNA 
polymerases mediate strand synthesis in the presence 
of lesions (e.g. abasic sites) on the parental strand. This 
allows replication to be completed in a timely manner 
but at the expense of generating mutations. 
 Transversion mutation: A mutation in which a purine is replaced by a 
pyrimidine (and vice versa). 
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Figure Legends  
Figure 1. Error-prone processing of genomic uracil downstream of A3-mediated 
cytosine deamination results in transitions, transversions or double strand breaks 
(DSBs). A3 mutation is a multistep process that begins with the exposure of ssDNA 
(shown here to occur either when the complementary strand is absent such as 
following resection at DSBs, or in transiently unwound DNA such as in transcription 
bubbles) to the activity of an A3 enzyme. Multiple deoxycytidines (usually within 
TpCpA/T/G motifs) may then be deaminated to deoxycytidines. The normal process 
of BER would then be removal of the base by UNG to yield an apyrimidinic (AP) site, 
'nicking' by endonuclease APE1 and then repair by XRCC1-recruited polymerases and 
ligases. Interruption of this process by replication prior to UNG-catalyzed base 
excision results in C>T transitions (left). More commonly, base excision occurs 
efficiently but the resulting AP site can be replicated over by translesion synthesis 
(TLS) polymerases, leading generally either to transitions or to transversions 
(centre), depending upon the polymerase involved. Deamination of bases on 
opposing strands could lead to DSBs, as occurs during AID-mediated CSR (right). 
Figure based on models presented in [5, 20-23]. 
 
Figure 2. Potential mechanisms exposing ssDNA to A3 activity 
Four potential mechanisms are shown by which ssDNA could become exposed to A3 
activity, resulting in mutagenesis, shown here when error-prone translesion 
synthesis (TLS) polymerases mediate replication over the abasic sites generated by 
UNG. Any or all of these mechanisms may account for both single mutations and for 
kataegis, represented here on rainfall plots (center) of intermutation distance 
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against the genomic locations of mutations for a breast cancer (BRCA_PD4107A), 
originally featured in the seminal kataegis paper of Nik-Zainal et al. [32]. The plots 
show a large multi Mb region (lower panel) of kataegis (over a region of 
chromothripsis). Zooming in (upper panel) we can see evidence of strand-switching: 
multi-kb showers of cytosine mutations on one strand (red dots) and then the other 
(blue dots). (1) BIR induced by a one-ended DSB occurring as a result of replication 
fork collapse. This mode of replication is conservative; all newly synthesized DNA is 
incorporated into the recipient chromosome (R), using the donor (D) as the 
template. Note that ssDNA is exposed on the recipient strand both during initial 
resection and during asynchronous synthesis as the replication bubble migrates 
often very large distances along the chromosome. (2) Bidirectional 5’-3’ resection 
during repair of double sided breaks creates ssDNA on opposing strands either side 
of the DSB. This could explain the strand-switching observed both in yeast models of 
kataegis [31] and in tumor samples such the example shown here. (3) Stretches of 
ssDNA can result from problems during replication, including polymerase blockage at 
replication forks as shown here. (4) R-loops are structures in which GC-rich coding 
strand DNA hybridizes with nascent mRNA, exposing the non-coding strand to 
deamination by AID. Figure based on models presented in [87] and references 
therein. 
 
Figure 3. Model depicting the possible causes and consequences of A3 mediated 
mutagenesis during tumor development. Based on the current literature we 
propose a speculative model in which multiple factors combine to cause off-target 
A3 activity and that this in turn drives further mutation and genomic instability, 
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fuelling tumor development. Note that TP53 mutations, genomic instability and DSBs 
have been proposed as both causes and consequences of A3 activity [35, 45]. 
Abbreviation: TSG, tumor suppressor gene. 
 
Box 1 Figure I. Evolution of the A3 gene family and distribution of the A3A_B 
polymorphism. 
(A) The A3 family has evolved solely within the mammalia, probably from a 
duplication of the ancestral AID gene. There are 3 ancient clades (A3Z1-A3Z3) that 
have fused and recombined to make the seven human A3 genes (A, B, C, D, F, G, 
H). Figure reproduced from [80] with permission from Dr Ignacio Bravo. 
(B) A deletion polymorphism produces a hybrid, A3A_B, in which the A3A CDS is 
fused to the A3B 3’UTR. The polymorphism is very rare in African populations but 
expanding to near fixation in Oceanian populations (arrows represent human 
migration out of Africa over the last approx. 100,000 years). Figure adapted from 
[81] with permission from Dr Evan Eichler. 
 
Figure 1
Click here to download high resolution image
Figure 2
Click here to download high resolution image
Figure 3
Click here to download high resolution image
Box Figure I
Click here to download high resolution image
